Lexington buys into bioventure funds
Abingworth Bioventures III and IV invested in bone and joint medication company Galápagos and women's health company Gynesonics, respectively.
13 November 2014•2 mins read
SECONDARIES INVESTOR
Register to unlock this content
Daily global secondaries market news and intelligence- Curated insights to keep you ahead of GP-led and LP-led secondaries
- Faster, data-driven decision making powered by our AI interface, 'Ask PEI'
- Access to proprietary research and reports
- Selected fund performance and investor activity data